LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

被引：0
|
作者：
Jackson, D. [1 ]
Lee, J. M. [2 ]
Adams, J. [1 ]
Gordois, A. [1 ]
机构：
[1] IMS Hlth, St Leonards, NSW, Australia
[2] Sanofi Aventis Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74342-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [21] Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis
    Wolowacz, S. E.
    Seal, B. S.
    Tangirala, M.
    CANCER RESEARCH, 2009, 69 (24) : 622S - 623S
  • [22] Impact of adjuvant chemotherapy with docetaxel for early breast cancer:: Cost-effectiveness analysis (CEA) of a docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in France
    Miadi-Fargier, H
    Le Pen, C
    Woronoff-Lemsi, MC
    Guastalla, JP
    Pivot, X
    Roché, H
    Pinguet, F
    Favier, B
    Gligorov, J
    Debrix, I
    Spielmann, M
    Antoine, EC
    Cadilhac, M
    De Pouvourville, GA
    VALUE IN HEALTH, 2005, 8 (06) : A36 - A37
  • [23] Cost effectiveness of adjuvant chemotherapy with cyclophosphamide plus methotrexate plus fluorouracil in patients with node positive breast cancer
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (02) : 111 - 116
  • [24] Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU + epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
    Berton-Rigaud, D.
    Roche, H.
    Penault-Llorca, F.
    Tubiana-Mathieu, N.
    Ferrero, J.
    Coudert, B.
    Milano, G. A.
    Mousseau, M.
    Homokos, H.
    Fumoleau, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
    Xu, Qiaoping
    Li Yuanyuan
    Zhu Jiejing
    Liu Jian
    Li Qingyu
    Chen Lingya
    Luo Ying
    Shi Changchen
    Li Yangling
    Yan Wei
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [26] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
  • [27] Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
    Qiaoping Xu
    Li Yuanyuan
    Zhu Jiejing
    Liu Jian
    Li Qingyu
    Chen Lingya
    Luo Ying
    Shi Changchen
    Li Yangling
    Yan Wei
    Cost Effectiveness and Resource Allocation, 19
  • [28] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [29] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [30] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
12345